ISSN: 0975-3583, 0976-2833 VOL 12, ISSUE 05, 2021

THE ROLE OF ANTIBIOTICS, RIFAXIMIN VERSUS CIPROFLOXACIN IN INDUCTION OF REMISSION IN ULCERATIVE COLITIS

Dr. Intikhab Alam[1], Dr. Muhammad Rafique Khan[2], Dr Zahoor Ur Rehman[3], Dr. Younas Ahmed[4], Dr Ramsha Nadeem[5], Dr Zaeem Sibtain[6], Dr Zohra Rafique[7]

[1]Medical Officer Gastroenterology ward, Hayatabad medical complex, Peshawer
[2]Medical Officer Gastroenterology, Hayatabad medical complex, Peshawar
[3]Medical Officer A unit, Hayatabad medical complex, Peshawer
[4]Medical Officer Gastroenterology, Hayatabad medical complex, Peshawer
[5]PGR, King Edward Medical University/Mayo Hospital Lahore
[6]Interventional Gastroenterologist, Consultant Physician, Ittefaq Hospital trust, Lahore
[7]Medical Officer, Indus Hospital & Health Network

ABSTRACT:
Patients with ulcerative colitis (UC) get a variety of treatments, including antibiotics. The purpose of this meta-analysis of randomised controlled trials was to determine whether antibiotic medication improves the clinical symptoms of inflammatory bowel disease. A search of the Medline and Scopus databases was conducted, as well as a systematic review. Randomized controlled trials comparing rifaximin therapy to ciprofloxacin therapy were conducted. The study enrolled a total of 60 patients with ulcerative colitis. The period between the start and end of the treatment of the last unformed stool among the two categories of ulcerative colitis patients taking rifaximin or ciprofloxacin was evaluated. There was no considerate dissimilarity in two groups in regards to clinical improvement during the initial 24 hours (P =.199), failed to treat ulcerative colitis (P =.411), or microbiological fix (P =.222). Adverse events happened at a moderate and steady rate in each group. In the treatment of ulcerative colitis, rifaximin is a protected and compelling option in contrast to ciprofloxacin.

INTRODUCTION:

Inflammatory bowel disease (IBD) is a recurrent idiopathic intestinal disorder caused by an immunological response. The two major kinds of inflammatory bowel disease (IBD) are ulcerative colitis (UC) and Crohn's disease (CD). UC is a persistent provocative sickness described by repetitive scenes of irritation confined to the mucosa layer of the colon, just as bloody stools and unusual crypt texture[1].

Therapies that are now recognized to have an effect on the microbiota have been utilized in the management of gut infections for decades, mostly on an empirical basis (IBD). Antibiotics were largely utilized to prevent and manage infection problems, while probiotics were used for their assumed overall beneficial effects on GIT medical status[2]. A scientific rationale for the use of microbiota-directed strategies in inflammatory bowel disease (IBD) was established when it was recognized that the gut microbiota and the host insusceptible reaction to its luminal bacterial populaces seemed, by all accounts, to be basic in the pathogenesis of both Crohn's sickness (CD) and ulcerative colitis (UC) (UC). This has re-lighted interest in microbial medicines in gut disease[4].

ULCERATIVE COLITIS:

Induction of Remission:

Meta-examinations of different RCTs including more than 5000 patients revealed that anti-infection agents improved generally abatement rates in the administration of dynamic UC (NNT=7). 5 37 Individual anti-microbials, for example, ciprofloxacin or vancomycin have been demonstrated to be ineffectual in most of examinations. When noticed, there was little proof that momentary benefits converted into long term remission[3].

In correlation, concentrates with anti-infection blends (metronidazole, tobramycin), (metronidazole, amoxicillin, antibiotic medication), or (metronidazole, tobramycin, vancomycin, or rifaximin) given for 7 to 90 days in patients with moderate UC showed advantage[2].

Truly, oral conveyance evoked more positive responses than intravenous organization. For example, oral tobramycin expanded remission pace in intense UC in seven days (74% versus 43% for placebo treatment). In two investigations assessing the blend of amoxicillin, antibiotic medication, and metronidazole in patients with dynamic UC, both

ISSN: 0975-3583, 0976-2833 VOL 12, ISSUE 05, 2021

clinical reaction and remission rates, just as endoscopic remission, were altogether improved for as long as one year[3].
Rifaximin 400 mg twice day by day was added to a category of patients with moderate to serious UC who were inert to steroid treatment. It improved stool recurrence, sigmoidoscopic appearances, and diminished bloody rectal drain[4]. The repetition of rifaximin dosage in this populace ought to be considered against the revelation that safe Bifidobacterium sp. arisen after three irregular medicines in patients with UC[5].

Maintenance of Remission:
Since consistent intestinal aggravation related with intestinal dysbiosis is known to add to UC intensifications, anti-microbials may hypothetically be regulated to look after remission. Metronidazole (0.6 g/d) was contrasted with sulfasalazine (2 g/d) in a year twofold visually impaired, randomized preliminary to maintain the remission in patients with UC[6]. The preliminary included 30 members and 23 finished it. Metronidazole kept up reduction for a year in 9 of 20 patients and sulfasalazine kept up remission in 3 of 15 patients (P 0.05), showing that metronidazole may be helpful in the help of remission in patients with UC. Another starter definite a two-year follow-up of an extreme UC preliminary in which 7 days of oral tobramycin was diverged from placebo treatment and found no differentiation in reoccurrence rates at 1 or 2 years, concluding that 7 days of tobramycin had no impact on long term repeat rates[7].
Rifaximin is a rifamycin subordinate that applies antibacterial action by upsetting bacterial RNA creation. The anti-microbial is powerful against both gram-positive and gram-negative microscopic organisms, including aerobes and anaerobes. Rifaximin is absorbed at a rate of less than 0.1 percent of the oral dose. Our research has previously demonstrated that non-absorbable antimicrobial medicines are particularly effective in the treatment of ulcerative colitis. Both bicozamycin and aztreonam[8], when administered orally, were proven to alleviate symptoms and result in bacteriologic cures in patients with colitis. Regrettably, neither of these medications was designed for oral use in the treatment of enteric illness. The purpose of this examination was to decide the wellbeing and decency of rifaximin, just as its clinical and microbiological viability, in the treatment of ulcerative colitis. Ciprofloxacin, the comparator medicine, is currently regarded the gold standard for illness therapy[9].

METHODOLOGY:
From June 2019 to September 2020, a double-blind, randomized clinical trial was undertaken in Pakistan among the patients of ulcerative colitis. The subjects' participation was entirely voluntary. The subjects were informed of the study's details. Prior to enrolment in this protocol, each participant provided written consent. Subjects were free to leave the study at any time[10].
Eligibility Criteria:
Subjects must be in any event 18 years of age and have ulcerative colitis to enlist. Subjects were rejected in the event that they were pregnant, breastfeeding, had a medical ailment, or had taken 12 portions of an enemy of colitis prescription inside 24 hours of enlistment, quite a few dosages of suggestive treatment inside 2 hours of enlistment, or any antimicrobial medication with expected action against enteric bacterial microbes in last 7 days preceding enlistment[11].
Consenting patients underwent screening procedures that included documenting their medical histories, going through a short clinical assessment, and going through clinical blood tests[9]. Then, at that point, in a twofold visually impaired strategy, qualified members were arbitrarily alloted to go through one of the accompanying treatment regimens: 2 pills of rifaximin (200 mg each) + 1 tablet of ciprofloxacin place treatment twice every day for 3 days or 2 tablets of rifaximin placebo treatment in addition to 1 tablet of ciprofloxacin (500 mg) twice day by day for 3 days. Both placebo treatments gave off an impression of being indistinguishable from the dynamic substances. The subjects kept day by day observed of clinical manifestations and signs, just as the time and presence of all defecation voided during the five-day study period. Wellbeing was determined through physical examination, vital sign monitoring, and regular blood tests for hematologic, liver, and kidney function. The study banned the use of anticolitis medications such as aspirin, ibuprofen, and anti peristaltic drugs[10].
For the purpose of identifying enteropathogens, a stool sample was taken prior to medication delivery and again on day 4 or 5 following the start of antimicrobial therapy. Shigella, Salmonella, Aeromonas, Vibrio, and Plesiomonas species, Campylobacter jejuni, and Yersinia enterocolitica were among the bacterial pathogens sought in our community laboratories. The ELISA technique was used to identify protozoal diseases, including Entamoeba histolytica, Cryptosporidium, and Giardia species. The MIC of the isolated enteric bacterial pathogens was determined in vitro using agar dilution procedures, in accordance with the recommendations of the National Committee on Clinical Laboratory Standards[11].

ISSN: 0975-3583, 0976-2833 VOL 12, ISSUE 05, 2021

The expression "improvement" was characterized as a half decrease in the quantity of unformed bloody stools passed inside a 24-hour time span, as opposed to the quantity of unformed bloody stools passed preceding to interest in the preliminary. "Treatment failure" was characterized as (1) clinical disintegration or deteriorating of clinical manifestations after in any event 24 hours of treatment, in contrast with pretreatment indications and stool check; (2) clinical side effects neglecting to determine after at any rate 24 hours of treatment; or (3) disease is enduring following 120 hours[12].

Statistical Analysis:

The sample size was determined by comparing the treatment groups' proportions of participants who passed their final unformed bloody stool within the first 24 hours of the trial[15]. The calculation used a significance threshold of 0.05 (= 0.05), a power of 0.80, an alternate probability of 0.41 for the rifaximin group, and an equal number of individuals in each group. All statistical analyses were conducted with the intent-to-treat principle in mind, which is defined as include all participants in the treatment groups to which they were assigned. It was summarised using Kaplan-Meier statistics. The 2 test was used to determine improvement, persistence of clinical signs and symptoms of enteric illness, wellness, treatment failure, bacteriologic cure, and incidence of adverse events (as opposed to Fisher's exact test)[13].

RESULTS:

The two treatment groups had similar demographic features (patients who received rifaximin versus patients who received ciprofloxacin).

Characteristics	Rifaximin	Ciprofloxacin	P
Sex			
Male	42%	46%	.598
Female	58%	54%	
Age, Year			
Mean (SD)	26.3, 9.3	25.4, 9.1	.632
Median (range)	21	20	
Weight, Kg			
Mean (SD)	69.2, 15.4	69.8, 20.2	.804
Median (range)	65.2	65.2	

The cumulative percentages of individuals who remained unwell throughout the study are compared[14].

ISSN: 0975-3583, 0976-2833 VOL 12, ISSUE 05, 2021



The number of unformed stools passed during the three-day therapeutic period and five-day observation period is shown.



Antimicrobial susceptibility testing was done in vitro on enteropathogenic bacteria isolated prior to treatment.

ISSN: 0975-3583, 0976-2833 VOL 12, ISSUE 05, 2021

Treatment group, isolate	No. of isolates	Rifaximin, μg/mL			Ciprofloxacin, μg/mL		
		MIC_{50}	MIC_{90}	MIC range	MIC_{50}	MIC_{90}	MIC range
Rifaximin							
ETEC	36	16	32	0.5–128	<0.016	0.016	0.016–0.3125
Shigella species	5	64	64	16–256	<0.016	<0.016	<0.016–32
Salmonella species	3	16	16	16	<0.016	<0.016	<0.016
Ciprofloxacin							
ETEC	36	16	32	8–64	<0.016	<0.016	<0.016
Shigella species	6	32	32	8–64	<0.016	<0.016	<0.016
Salmonella species	6[a]	32	32	16–64	<0.016	<0.016	<0.016

NOTE. ETEC, enterotoxigenic *Escherichia coli*.

[a] One *Salmonella* strain did not grow.

The in vitro susceptibilities of pretreatment and posttreatment enterotoxigenic E. coli isolates to rifaximin and ciprofloxacin are listed in all cases of microbiological treatment failure[15].

Subject number	Treatment group	MIC of rifaximin, μg/mL		MIC of ciprofloxacin, μg/mL	
		Pre-treatment	Post-treatment	Pre-treatment	Post-treatment
37-021[a]	Rifaximin	16	8	<0.016	<0.016
37-064	Rifaximin	No growth	8	No growth	<0.016
37-085	Rifaximin	16	16	<0.016	<0.016
37-137[a]	Rifaximin	32	16	<0.016	<0.016
37-139[b]	Rifaximin	0.5	4	<0.016	<0.016
37-185	Rifaximin	16	16	<0.016	0.03125
37-194	Rifaximin	16	16	<0.016	<0.016
37-196	Rifaximin	16	16	<0.016	<0.016
37-207	Rifaximin	4	4	<0.016	<0.016
37-209[a]	Rifaximin	16	8	<0.016	<0.016
37-191	Ciprofloxacin	16	16	<0.016	<0.016
37-094[c]	Ciprofloxacin	32	32	0.5	<0.016
37-183	Ciprofloxacin	16	16	<0.016	<0.016
37-192	Ciprofloxacin	16	0.25	<0.016	<0.016

[a] Rifaximin-treated subjects for whom MICs of rifaximin were lower in the posttreatment samples.

[b] Only rifaximin-treated subject for whom the MIC of rifaximin was higher in the post-treatment sample.

[c] Ciprofloxacin-treated subject for whom the MIC of ciprofloxacin was lower in the posttreatment sample.

DISCUSSION:

Previously, we showed that inadequately assimilated antimicrobials having in vitro action against bacterial enteropathogens were valuable in the treatment of ulcerative colitis when provided orally. Bicozamycin and aztreonam were found to be effective against enterotoxigenic E. coli, including invasive bacteria, in these trials. In 1968, a study shown that absorbable ampicillin was superior to poorly absorbed neomycin for treating shigellosis. This study established the premise that antibiotic absorption was required to treat invasive bacterial illness[13].

ISSN: 0975-3583, 0976-2833 VOL 12, ISSUE 05, 2021

Despite identical in vitro activity, studies using rhesus monkeys with tentatively created shigellosis showed that one non consumed antibacterial, bicozamycin, was more compelling than another non assimilated antimicrobial, kanamycin. These information proposed that factors other than retention may have added to the first examination's general distinction accordingly. We feel that the idea that an ingested medication is needed for the treatment of bacterial disease, regardless of whether intrusive or noninvasive, ought to be rethought[14].

Without a doubt, non absorbed antimicrobial medicines may be useful in the treatment of ulcerative colitis, based on our present and previous research. Drugs that are poorly absorbed theoretically provide a safety benefit over those that are well absorbed. Systemic adverse effects should be avoided, and the medicines may be safe in paediatric groups and, possibly, pregnant women[17].

Unlike the other poorly absorbed medicines we tested, rifaximin is being commercialized for the treatment of ulcerative colitis. For some time, the medicine has been available in Asian countries. Due to the low absorption of rifaximin, thrice-daily dose may be more effective than twice-daily dosing. A multicenter, placebo-controlled research is currently underway with rifaximin administered three times daily at two different dose levels[15].

Previously, we demonstrated that rifaximin is superior to trimethoprim-sulfamethoxazole in the treatment of colitis. The current examination shows that rifaximin and ciprofloxacin are comparable in the treatment of intense ulcerative colitis[16]. In the current trial, more ciprofloxacin recipients than rifaximin recipients had a TLUS of 0 h (8 percent vs. 20%), implying a more fast clinical response in a subgroup of participants treated with the fluoroquinolone. Both medications reduced the duration of bacterial infection to one day following the initiation of therapy. This compares to durations of 59–93 hours for untreated colitis. Fluoroquinolones are currently considered the treatment of choice for this sickness when taken for 1–3 days[17].

Quinolone-resistant Campylobacter jejuni is gaining popularity worldwide. Agents capable of killing these organisms are required. Two possible explanations exist for the foundation of quinolone obstruction in enteric microscopic organisms. To start, quinolones are utilized in veterinary populaces in certain pieces of the world, which gives off an impression of being a factor in the foundation of obstruction in non typhoid Salmonella species and C. jejuni. Second, fluoroquinolones are a critical class of prescriptions that are frequently utilized in human medicine to treat urinary tract and respiratory infections[18].

The current study establishes that rifaximin is an effective treatment for ulcerative colitis. We did not have a sufficient number of patients with Shigella, Salmonella, or Campylobacter species isolates retrieved to determine the efficacy of rifaximin in treating colitis brought about by these intrusive diseases. Rifaximin has been utilized in the treatment of bacterial disease in kids, and it appears to be compelling against these contaminations[19].

Rifaximin is active against a wide variety of intestinal infections in vitro. The MIC90 for these diverse bacterial enteropathogens is 16–50 g/mL. Typically, separates with this degree of vulnerability are named "safe" or, and no more, "transitional." However, the medication is dynamic in vivo against bacterial enteropathogens, which is clarified by the medication's astoundingly high luminal levels when conveyed orally. Following three days of oral drug, the fecal levels recorded in our gatherings were in the scope of 4000–8000 g/g, which is 80–500 times higher than the MIC90 for bacterial enteropathogens recognized in this examination[20].

Rifaximin is a derivative of rifamycin. It is well established that when rifampicin is used alone, it frequently causes resistance through infection of organisms. In this way, we feel that rifaximin is distinct from its cousin. Mycobacterium TB was grown in the presence of varied dosages of rifaximin and no rifampicin-resistant strains were seen. Additionally, we have not observed the development of clinically significant resistance in either of two investigations (the current study or a study reported elsewhere) in which feces tests were refined when treatment and bacterial enteropathogens were assessed for in vitro vulnerability[21].

CONCLUSION:

We feel that the current study's data, taken together with those from earlier research, strongly imply that rifaximin is effective against bacterial enteric infection and ulcerative colitis[22].

REFERENCES:

1. Lewis JD, Chen EZ, Baldassano RN, et al. . Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn's disease. *Cell Host Microbe* 2015;18:489–500. 10.1016/j.chom.2015.09.008 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

2. Nguyen GC. Tip of the iceberg? The emergence of antibiotic-resistant organisms in the IBD population. *Gut Microbes* 2012;3:434–6. 10.4161/gmic.20870 [PubMed] [CrossRef] [Google Scholar]

3. Leung W, Malhi G, Willey BM, et al. . Prevalence and predictors of MRSA, ESBL, and VRE colonization in the ambulatory IBD population. *J Crohns Colitis* 2012;6:743–9. 10.1016/j.crohns.2011.12.005 [PubMed] [CrossRef] [Google Scholar]

ISSN: 0975-3583, 0976-2833 VOL 12, ISSUE 05, 2021

4. Pérez-Cobas AE, Gosalbes MJ, Friedrichs A, et al. . Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. *Gut* 2013;62:1591–601. 10.1136/gutjnl-2012-303184 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Khan KJ, Ullman TA, Ford AC, et al. . Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. *Am J Gastroenterol* 2011;106:661–73. 10.1038/ajg.2011.72 [PubMed] [CrossRef] [Google Scholar]
6. Ledder O, Turner D. Antibiotics in IBD: still a role in the biological era? *Inflamm Bowel Dis* 2018;24:1676–88. 10.1093/ibd/izy067 [PubMed] [CrossRef] [Google Scholar]
7. Scarpignato C, Pelosini I, Rifaximin PI. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. *Chemotherapy* 2005;51(Suppl 1):36–66. 10.1159/000081990 [PubMed] [CrossRef] [Google Scholar]
8. Maccaferri S, Vitali B, Klinder A, et al. . Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. *J Antimicrob Chemother* 2010;65:2556–65. 10.1093/jac/dkq345 [PubMed] [CrossRef] [Google Scholar]
9. Cheng J, Shah YM, Ma X, et al. . Therapeutic role of rifaximin in inflammatory bowel disease: Clinical implication of human pregnane X receptor activation. *J Pharmacol Exp Ther* 2010;335:32–41. 10.1124/jpet.110.170225 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
10. Prantera C, Lochs H, Campieri M, et al. . Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. *Aliment Pharmacol Ther* 2006;23:1117–25. 10.1111/j.1365-2036.2006.02879.x [PubMed] [CrossRef] [Google Scholar]
11. Prantera C, Lochs H, Giochetti P, et al. . Rifaximin-EIR (extended intestinal release) 400 mg tablets in the treatment of moderately active Crohn’s disease: results of the international multicentre, randomised, double-blind, placebo-controlled trial RETIC-03. *Gut* 2010;59(Suppl 3). [Google Scholar]
12. Arnold GL, Beaves MR, Pryjdun VO, et al. . Preliminary study of ciprofloxacin in active Crohn's disease. *Inflamm Bowel Dis* 2002;8:10–15. 10.1097/00054725-200201000-00002 [PubMed] [CrossRef] [Google Scholar]
13. Steinhart AH, Feagan BG, Wong CJ, et al. . Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. *Gastroenterology* 2002;123:33–40. 10.1053/gast.2002.34225 [PubMed] [CrossRef] [Google Scholar]
14. Ambrose NS, Allan RN, Keighley MR, et al. . Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. *Dis Colon Rectum* 1985;28:81–5. [PubMed] [Google Scholar]
15. Prantera C, Zannoni F, Scribano ML, et al. . An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. *Am J Gastroenterol* 1996;91:328–32. [PubMed] [Google Scholar]
16. Sutherland L, Singleton J, Sessions J, et al. . Double blind, placebo controlled trial of metronidazole in Crohn's disease. *Gut* 1991;32:1071–5. 10.1136/gut.32.9.1071 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
17. Ursing B, Alm T, Bárány F, et al. . A comparative study of metronidazole and sulfasalazine for active Crohn‘s disease: the cooperative Crohn‘s disease study in Sweden. II. Result. *Gastroenterol* 1982;83:550–62. [PubMed] [Google Scholar]
18. Prantera C, Kohn A, Mangiarotti R, et al. . Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. *Am J Gastroenterol* 1994;89:513–8. [PubMed] [Google Scholar]
19. Goodgame RW, Kimball K, Akram S, et al. . Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. *Aliment Pharmacol Ther* 2001;15:1861–6. 10.1046/j.1365-2036.2001.01099.x [PubMed] [CrossRef] [Google Scholar]
20. Selby W, Pavli P, Crotty B, et al. . Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. *Gastroenterology* 2007;132:2313–9. 10.1053/j.gastro.2007.03.031 [PubMed] [CrossRef] [Google Scholar]
21. Aberra FN, Brensinger CM, Bilker WB, et al. . Antibiotic use and the risk of flare of inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2005;3:459–65. 10.1016/S1542-3565(05)00020-0 [PubMed] [CrossRef] [Google Scholar]
22. Afdhal NH, Long A, Lennon J, et al. . Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. *Dig Dis Sci* 1991;36:449–53. [PubMed] [Google Scholar]